WebA live-attenuated vaccine targeting SARS-CoV-2 infection, which can be administered through the nose, has shown promise in preclinical animal studies carried out by researchers in Berlin. In an article published April 3, 2024, in Nature Microbiology, the authors reported that the COVID-19 vaccine candidate – sCPD9 – triggered the most ... WebTargeted cancer therapies represent a milestone towards personalized treatment as they function via inhibition of cancer-specific alterations. Polymerase θ (POLQ), an error-prone translesion polymerase, also involved in DNA double-strand break (DSB) repair, is often upregulated in cancer. POLQ is synthetic lethal with various DNA repair genes, including …
Biopoin European Medicines Agency
WebAug 27, 2024 · Abstract. DNA polymerase theta (POLQ)-mediated end joining (TMEJ) is a distinct pathway for mediating DNA double-strand break (DSB) repair. TMEJ is required for the viability of BRCA-mutated cancer cells.It is crucial to identify tumors that rely on POLQ activity for DSB repair, because such tumors are defective in other DSB repair pathways … Web15 hours ago · Anti-slip leg-locking mechanisms. Durability that stands up to light wind, sand, and water. Auto light detection with the camera module lets the camera then figure … palpable irony
Repare Therapeutics Inc. (RPTX) - Stock Analysis
WebNov 17, 2024 · Organically coupled with the identification of such targets in the virus is the discovery of therapeutics. Specifically, researchers in the broader group are trying to design antibodies for the virus—that is, as Ramanathan put it, “proteins that can bind to specific epitopes or regions that innately make the virus vulnerable to attack from our immune … WebMar 31, 2024 · Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies … WebEpiAxis is developing a series of products targeting LSD1, PKC theta and PD1/PDL1. ... Our intellectual property Our wholly owned IP is broad and includes strong coverage for our therapeutic portfolio and includes a dominating position for LSD1 inhibitors used in combination with surgery, radiotherapy or chemotherapy or immuno-therapy. server emule morphxt